EAU 2017: State-of-the-art lecture Levels of competence in mpMRI reporting
London, England (UroToday.com) Dr. Puech gave a talk on multiparametric MRI (mpMRI) reporting.
We as urologist expect several things from the radiologist reading and reporting mpMRI of the prostate. The mpMRI should give good quality results and enable us to locate suspicious lesions with high probability of being significant prostate cancer. The images should allow us to plan targeted biopsies, treatment and adequate follow-up. The results should be reproducible and standardized. Finally, the mpMRI produced report will hopefully allow us to convey the results to the patients in a simple manner as well.
EAU 2017: State-of-the-art lecture : What do urologists need to know about mpMRI targeted biopsy?
London, England (UroToday.com) Dr. Boxler presented his opinion on what urologists need to know about multiparametric MRI (mpMRI) targeted biopsy.
EAU 2017: Discussant: Is PIRADS 2.0 standardized enough?
London, England (UroToday.com) Dr. Polascik gave a presentation on PIRADS ver. 2 outlining differences from ver. 1, limitations and possible solutions. Several studies were initially presented, comparing performance of PIRADS 1 to PIRADS 2.
EAU 2017: Reading and interpreting mpMRI: PIRADS 2.0
London, England (UroToday.com) Dr. Rooij gave a short and well organized presentation on the reading and interpretation of the PIRADS ver. 2. PI-RADS (Prostate Imaging Reporting and Data System) are the clinical guidelines for multiparametric MRI of the prostate to detect clinically significant prostate cancer.
EAU 2017: European Society of Urogenital Radiology (ESUR) lecture PI-RADS in clinical practice including differential diagnoses in prostate imaging
London, England (UroToday.com) In her presentation Dr. Theony, a radiologist from Berne, presented a short summary on PI-RADS implementation in clinical practice of prostate imaging. PI-RADS (Prostate Imaging Reporting and Data System) are the clinical guidelines for multiparametric MRI of the prostate to detect clinically significant prostate cancer.
EAU 2017: Metastases and death after 15 year of follow-up in men with screen-detected low-risk prostate cancer treated with protocol based active surveillance, radical prostatectomy or radiotherapy (804)
London, England (UroToday.com) Despite recent publicity regarding the results of the ProtecT trial, which demonstrated no difference in PCa-specific survival after a median of 10 yr follow-up (FU) between surgery (RP), radiotherapy (RT) and active monitoring (AM) in men with screen detected localized prostate cancer (PCa), the primary issue with the study remains that the active monitoring arm is significantly different than active surveillance.
EAU 2017: MRI as a follow up tool in active surveillance: results from an MRI-defined active surveillance cohort
London, England (UroToday.com) Active surveillance (AS) has become a mainstay of therapy for low-volume, low-risk prostate cancer, and in some institutions, it is also utilized for low-volume intermediate risk disease. However, the introduction of multiparametric MRI (mpMRI) has significantly changed our evaluation of the prostate, both in men with elevated PSA (undiagnosed prostate cancer) and in men on active surveillance.